3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Pancreatic Neoplasms
57
Carcinoma, Non-Small-Cell Lung
34
Urinary Bladder Neoplasms
29
Neoplasm Metastasis
20
Lung Neoplasms
19
Ovarian Neoplasms
18
Lymphoma, Large B-Cell, Diffuse
18
Cholangiocarcinoma
15
Biliary Tract Neoplasms
14
Triple Negative Breast Neoplasms
13
Neoplasms
13
Nasopharyngeal Carcinoma
13
Colorectal Neoplasms
12
Breast Neoplasms
12
Carcinoma, Transitional Cell
11
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
9
Fallopian Tube Neoplasms
9
Gallbladder Neoplasms
8
Sarcoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Bile Duct Neoplasms
6
Osteosarcoma
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
4
Melanoma
4
Hodgkin Disease
4
Colonic Neoplasms
4
Interventions
pembrolizumab
1
enfortumab vedotin
1
Radiation Dose Hypofractionation
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Diseases
×
Gemcitabine
×
90 days
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled